default author photo

Noah Zimmermann

University of Hamburg - University Medical Center Hamburg-Eppendorf

Martinistrasse 52

Hamburg, D - 20246

Germany

SCHOLARLY PAPERS

1

DOWNLOADS

31

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Enhanced Overall and Progression-Free Survival in Advanced Melanoma Patients undergoing Targeted Therapy alongside Antithrombotic Treatment – Insights from a Multicenter Study involving 1,296 Patients from the Prospective Skin Cancer Registry ADOReg

Number of pages: 26 Posted: 31 Oct 2025
University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Kiel, affiliation not provided to SSRN, University of Tübingen, University Hospital Erlangen, University Hospital Mühlenkreiskliniken Minden, University of Duisburg-Essen - University Hospital Essen, affiliation not provided to SSRN, Elbe Kliniken Buxtehude, affiliation not provided to SSRN, Helios Klinikum Erfurt, Heidelberg University - Department of Dermatology, affiliation not provided to SSRN, Universitat Regensburg, Saarland University - Medical School, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Freiburg, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf and University Medical Center Hamburg- Eppendorf
Downloads 31 (1,304,549)

Abstract:

Loading...

melanoma, targeted therapy, BRAF and MEK inhibitors, Anticoagulation, Direct oral anticoagulants (DOACs), Factor Xa inhibitors, Progression-free survival (PFS), Overall survival (OS), Platelet aggregation inhibition, Venous thromboembolism (VTE), Immunothrombosis